TEPOTINIB for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 180 adverse event reports in the FDA FAERS database where TEPOTINIB was used for Lung neoplasm malignant.
Most Reported Side Effects for TEPOTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 117 | 17.5% | 117 | 11 |
| Oedema peripheral | 82 | 12.3% | 13 | 21 |
| Diarrhoea | 57 | 8.6% | 4 | 12 |
| Renal impairment | 57 | 8.6% | 3 | 15 |
| Oedema | 56 | 8.4% | 6 | 12 |
| Fatigue | 53 | 8.0% | 1 | 9 |
| Disease progression | 50 | 7.5% | 28 | 9 |
| Nausea | 43 | 6.5% | 7 | 10 |
| Off label use | 42 | 6.3% | 11 | 10 |
| Peripheral swelling | 32 | 4.8% | 2 | 4 |
| Blood creatinine increased | 30 | 4.5% | 7 | 3 |
| Decreased appetite | 27 | 4.1% | 5 | 8 |
| Dyspnoea | 20 | 3.0% | 1 | 6 |
| Pleural effusion | 18 | 2.7% | 2 | 10 |
| Interstitial lung disease | 16 | 2.4% | 6 | 5 |
Other Indications for TEPOTINIB
Product used for unknown indication (175)
Non-small cell lung cancer (150)
Lung adenocarcinoma (40)
Non-small cell lung cancer metastatic (33)
Lung cancer metastatic (16)
Lung adenocarcinoma stage iv (13)
Non-small cell lung cancer recurrent (12)
Lung carcinoma cell type unspecified stage 0 (9)
Non-small cell lung cancer stage iv (9)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
OSIMERTINIB (4,754)
NIVOLUMAB (4,197)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)